Form 4: Hinge Health Director Sells Class A Common Stock

Hinge Health Director Kristina M. Leslie reported sales of Class A Common Stock totaling 6,000 shares over two days.

Summary

• Kristina M. Leslie, a Director of Hinge Health, Inc. (HNGE), reported transactions involving the sale of Class A Common Stock.
• On November 18, 2025, 2,187 shares of Class A Common Stock were sold at a price of $40.4556 per share.
• Following this transaction, Leslie beneficially owned 32,813 shares of Class A Common Stock.
• On November 19, 2025, an additional 3,813 shares of Class A Common Stock were sold at a weighted average price of $43.603 per share.
• The sale price range for the November 19, 2025 transaction was between $43.51 and $43.73.
• After both reported transactions, Leslie beneficially owns 29,000 shares of Class A Common Stock.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The filing reports routine insider stock sales by a director, often pre-planned, which is generally neutral in sentiment as it doesn't necessarily reflect a change in company fundamentals.

Future Outlook

NA

Management Comments

• The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Industry Context

This filing reports a routine insider transaction by a director of Hinge Health, Inc., a digital musculoskeletal care company. Such transactions are common across industries and are typically part of personal financial planning or diversification strategies, especially when executed under a Rule 10b5-1 plan.

Stakeholder Impact

• Shareholders: May interpret director sales differently, though the transactions were pre-planned under Rule 10b5-1, which often mitigates negative perceptions.

Key Dates

Recommendation

The filing details routine, pre-planned insider sales by a director. While insider sales can sometimes be a negative signal, these transactions are often part of personal financial planning or diversification strategies and do not necessarily indicate a change in the company's fundamental outlook. Investors should consider this information in the broader context of the company's performance and other market factors before making investment decisions.

Keywords

Hinge Health, HNGE, Insider Trading, Form 4, Stock Sale, Director, Kristina Leslie, Rule 10b5-1